Antiviral Drugs

Approx. Rs 1,000 / PieceGet Latest Price

Product BrochureProduct Details:

INTRODUCTIONEntavir 0.5mg Tablet is used in the treatment of HIV infection and chronic hepatitis B virus (HBV) infection. It prevents the multiplication of virus in human cells. This stops the virus from producing new viruses and clears up your infection.

Entavir 0.5mg Tablet is not a cure for HIV or AIDS and only helps to decrease the amount of HIV in your body. This helps to lower your risk of getting HIV-related complications and improves your lifespan. It is prescribed in combination with other HIV medicines. Your doctor will recommend the best medicines for you and will decide the doses that you need. Follow carefully the instructions for all the medicines that you are given. It can be taken with or without food. Taking all these medicines regularly at the right times greatly increases their effectiveness and reduces the chances of HIV becoming resistant to them. It is important not to miss doses and to keep taking them until your doctor tells you it is safe to stop.

Common side effects of this medicine include headache, nausea, vomiting, stomach pain, fatigue, diarrhea, and rash. These are usually not serious but tell your doctor if they bother you or do not go away. Rarely, some people may experience a skin reaction or liver damage. Your doctor will closely monitor you for these in the initial period of treatment.

Before taking it, tell your doctor if you have any skin problems or liver or kidney disease. While using it, you may need regular blood tests to check your blood counts and liver function. Avoid drinking alcohol as it may increase your risk of liver damage. Pregnant or breastfeeding mothers should consult their doctor before using this medicine. Do not have unprotected sex or share personal items like razors or toothbrushes, if you are HIV positive. Talk to your doctor about safe ways like condoms to prevent HIV transmission during sex.

Approx. Rs 1,385 / PackGet Latest Price

Product Details:

Sevelamer carbonate is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer carbonate is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.
What is Renvela and how is it used?

Renvela is a prescription medicine used to treat the symptoms of Serum Phosphorus Regulation in patients with chronic kidney disease (CKD) who are on dialysis. Renvela may be used alone or with other medications.

Renvela belongs to a class of drugs called PO4 Scavengers.

It is not known if Renvela is safe and effective in children younger than 6 years of age.

What are the possible side effects of Renvela?

Renvela may cause serious side effects including:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• choking,
• trouble swallowing,
• black, bloody or tarry stools,
• severe constipation with stomach pain, and
• constipation that gets worse or does not clear up

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Renvela include:

• nausea,
• vomiting,
• stomach pain,
• loss of appetite,
• upset stomach,
• gas,
• bloating,
• diarrhea,
• constipation,
• tired feeling,
• itching, and
• joint pain

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Renvela. For more information, ask your doctor or pharmacist.

Approx. Rs 1,999 / BottleGet Latest Price

Product Details:

Gets DCGI nod to manufacture and market an investigational oral antiviral.

Hetero, a vertically integrated pharmaceutical organisation, launched Molnupiravir capsules 200 mg (Movfor).

Molnupiravir is an investigational oral antiviral for high risk adult Covid-19 patients.

The Hyderabad-based company has received approval from the Drug Controller General of India (DCGI) to manufacture and market Molnupiravir capsules 200 mg (Movfor).

Molnupiravir, an investigational oral antiviral, is indicated for restricted emergency use in India to treat adult patients with Covid-19 and with SpO2 93% and who have a high risk of disease progression.

Hetero’s Movfor will be made available in a 40 capsule pack (200 mg per capsule) and will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its strong distribution network across the country.

B. Partha Saradhi Reddy, Chairman, Hetero Group of Companies, said: “This approval consolidates India’s efforts to address the world’s greatest health threats, i.e., Covid-19. Improving access to critical medicines will always remain the highest of priorities to us."

Under the aegis of ‘Make in India’ campaign, commercial production of ‘Movfor’ will be undertaken at Hetero’s ”world-class facilities in Telangana and Himachal Pradesh, where it is ensured to meet the highest quality standards,'' he added.

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses, including SARS-CoV2, the causative agent of Covid-19

Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University. Since being licensed by Ridgeback, all funds used for developing EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and MSD.

Hetero entered into a non-exclusive voluntary licensing agreement with MSD to manufacture and distribute investigational oral therapeutic antiviral drug ‘Molnupiravir’ for the treatment of Covid-19. Under this licensing deal, Hetero will be allowed to expand access to Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorization by local regulatory agencies.

Hetero completed a phase 3 clinical trial (approved by CDSCO) in about 1218 Covid-19 patients, the data of which was approved by the subject expert committee (SEC) and recommended for marketing authorisation. Subsequently, CDSCO provided the approval for manufacturing and marketing.